Biomarin Pharmaceutical (BMRN) Current Assets (2009 - 2026)
Biomarin Pharmaceutical's (BMRN) quarterly Current Assets came in at $4.6 billion in Q1 2026, up 32.79% YoY from $3.5 billion in Q1 2025, and up 16.48% on a QoQ basis from $4.0 billion in Q4 2025.
Biomarin Pharmaceutical (BMRN) Current Assets (2009 - 2026) Analysis & Trends
Biomarin Pharmaceutical (BMRN) has 18 years of Current Assets data on file, last reported at $4.6 billion in Q1 2026.
- Quarterly Current Assets rose 32.79% year-over-year to $4.6 billion in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $4.6 billion (up 32.79% YoY) and the FY2025 annual result came in at $4.0 billion, up 22.31% from the prior year.
- Current Assets advanced to $4.6 billion in Q1 2026, from $4.0 billion in the prior quarter.
- In the past five years, Current Assets ranged from a high of $4.6 billion in Q1 2026 to a low of $2.4 billion in Q1 2022.
- A 5-year average of $3.2 billion and a median of $3.0 billion in 2024 frame the typical range for Current Assets.
- Annual changes were most pronounced in 2024 — Current Assets rose 3.43% — and 2026, when it surged 32.79%.
- Tracing BMRN's Current Assets over 5 years: stood at $2.8 billion in 2022, then grew by 7.44% to $3.0 billion in 2023, then increased by 9.35% to $3.2 billion in 2024, then rose by 22.31% to $4.0 billion in 2025, then increased by 16.48% to $4.6 billion in 2026.
- The last three Current Assets figures came in at $4.6 billion (Q1 2026), $4.0 billion (Q4 2025), and $3.9 billion (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 12.54 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 18.45 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 8.07 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 4.03 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 7.22 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 11.83 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 1.76 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 4.62 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 1.63 Bn |
| 10 | Biomarin Pharmaceutical | 13.04 Bn | 12.16 Bn | 786.91 Mn | 3.97 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 3.97 Bn |
| Mar 31, 2026 | 4.61 Bn |
| Dec 31, 2025 | 3.95 Bn |
| Sep 30, 2025 | 3.85 Bn |
| Jun 30, 2025 | 3.81 Bn |
| Mar 31, 2025 | 3.47 Bn |
| Dec 31, 2024 | 3.23 Bn |
| Sep 30, 2024 | 3.06 Bn |
| Jun 30, 2024 | 3.26 Bn |
| Mar 31, 2024 | 2.99 Bn |
| Dec 31, 2023 | 2.96 Bn |
| Sep 30, 2023 | 2.96 Bn |
| Jun 30, 2023 | 2.95 Bn |
| Mar 31, 2023 | 2.84 Bn |
| Dec 31, 2022 | 2.75 Bn |
| Sep 30, 2022 | 2.68 Bn |
| Jun 30, 2022 | 2.52 Bn |
| Mar 31, 2022 | 2.39 Bn |
| Dec 31, 2021 | 2.27 Bn |
| Sep 30, 2021 | 2.31 Bn |